MetaVia Inc. Implements 1-for-11 Reverse Stock Split to Enhance Listing Compliance

MetaVia Inc. Implements 1-for-11 Reverse Stock Split

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company, recently made headlines as it prepared to execute a 1-for-11 reverse stock split of its common stock effective at 5:00 PM ET on December 4, 2025.

Key Details of the Reverse Stock Split

The decision for this reverse stock split comes after a proposal was approved at the Company's annual meeting of stockholders held on June 30, 2025. The proposal allowed for a reverse stock split ratio ranging from 1-for-5 to 1-for-30, with the final determination made by the Company's Board of Directors. Ultimately, a ratio of 1-for-11 was chosen.

This move is aimed at reducing the outstanding shares of common stock, which is essential for enabling MetaVia to align with Nasdaq’s continued listing requirements. Following the reverse split, the number of shares outstanding will decrease dramatically from approximately 25.4 million to about 2.3 million shares. Additionally, this split maintains the par value at $0.001 per share, ensuring that the market reacts favorably to the adjustment.

Impact on Shareholders

For current shareholders, every 11 shares they own will be consolidated into one share. This conversion will not alter the total market value of their holdings; however, any fractional shares resulting from the split will be rounded down to the nearest whole share. These fractions will instead be converted into cash based on the market value at the close of trading on the last business day prior to the stock split.

Ongoing Trading on Nasdaq

After the split adjusts, MetaVia's common stock will continue trading on Nasdaq under its existing symbol, "MTVA," although it will now reflect the adjusted share count. The new CUSIP number for the stock following the reversal will be 64132R 503, as the transition takes effect.

About MetaVia

MetaVia Inc. is dedicated to addressing the pressing needs associated with cardiometabolic diseases. Currently, the company is in the process of developing innovative therapies, including DA-1726, aimed at treating obesity, and vanoglipel (DA-1241) targeted at addressing Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 functions as a dual agonist, activating both GLP1R and GCGR receptors to potentially enhance weight loss outcomes due to its unique mechanism that also promotes energy expenditure.

Preliminary Phase 1 trial results for DA-1726 indicate promising efficacy in weight loss and glucose control compared to existing treatment options.

On the other hand, vanoglipel has shown a favorable influence on liver conditions in pre-clinical studies, exhibiting benefits in liver inflammation and lipid metabolism, thus retaining critical prospects for treating related diseases in future clinical settings.

For further details, stakeholders are encouraged to visit MetaVia's official website for up-to-date investor information as well as to review the definitive proxy statement filed with the Securities and Exchange Commission on June 10, 2025.

Conclusion

The reverse stock split is seen as a strategic move to enhance the market position of MetaVia Inc. This consolidation reflects an ongoing commitment to not only meeting regulatory standards but also in creating a solid foundation for future growth in the field of biotechnology. As the company forges ahead with its promising pipeline, investors and industry observers alike will be watching closely to see how these developments unfold with MetaVia's innovative therapeutic candidates.